Tai Chi Chih & Varicella Zoster Immunity NCT00029484

Clinical Trial Details — Status: Completed

Administrative data
NCT number	NCT00029484
Other study ID #	R21AT000255-01
Secondary ID
Status	Completed
Phase	Phase 2
First received	January 11, 2002
Last updated	August 17, 2006

Study information
Verified date	July 2006
Source	National Center for Complementary and Integrative Health (NCCIH)
Contact	n/a
Is FDA regulated	No
Health authority	United States: Federal Government
Study type	Interventional

Clinical Trial Summary

A randomized control trial testing whether a relaxation response based intervention, Tai Chi Chih, will affect Varicella Zoster Virus (VZV) specific immunity measures of psychological adaptation and health function in the older adult.

Description:

Both the incidence and severity of Herpes Zoster (HZ) or "Shingles" increase markedly with increasing age, is a painful condition, due to a decline in Varicella Zoster Virus (VZV) specific immunity. Considerable evidence further shows that psychological stresses salient in the older adult correlate with impairments of cellular immunity.

The investigators have observed that Varicella Zoster Immunity is always decreased in individuals with major depression. Moreover, our preliminary data indicates that the presence of depressive symptoms in older adults is associated with a decline of VZV responder cell frequency (VZV-RCF). Taken together, the untoward effects of age and depressive symptoms on VZV immunity raise the question as to whether an alternative medicine intervention might augment VZV specific immunity in the older adult. We have preliminarily shown that administration of a relaxation-response based intervention, Tai Chi Chih (TCC), results in improvements in health functioning and VZV immunity in older adults as compared to controls. TCC is a slow moving meditation comprised of twenty separate standardized movements for use in elderly populations.

This proposed controlled clinical trial aims to: 1) determine whether the practice of TCC for 16 weeks influences Varicella Zoster Virus (VZV) immunity; 2) demonstrate that TCC can produce significant changes in psychological adaptation, health behaviors, and health functioning and well-being; and 3) assess whether changes in psychological adaptation, health behaviors, and health functioning correlate with changes in VZV immunity following TCC in older adults.

We hypothesize that this behavioral intervention that prioritizes treatment of excessive physiological arousal can influence one's affective state with effects on cellular immunity. By standardization of training and practice schedules, TCC offers an important advantage over prior relaxation response based therapies. Focus on older adults at increase risk for HZ and assay of VZV specific cellular immunity has implications for understanding the impact of behavioral factors and an alternative medicine intervention on a clinically relevant endpoint and the ability of the immune system to respond to antigens of infectious pathogens.

Recruitment information / eligibility
Status	Completed
Enrollment	70
Est. completion date
Est. primary completion date
Accepts healthy volunteers	Accepts Healthy Volunteers
Gender	Both
Age group	60 Years to 80 Years
Eligibility	History of Varicella or long-term resident (greater than or equal to 30 years) in the continental United States.

Study Design

Allocation: Randomized

Related Conditions & MeSH terms

Intervention

Behavioral:
• Tai chi chih

Locations
Country	Name	City	State
United States	University of California, San Diego	San Diego	California

Sponsors *(1)*
Lead Sponsor	Collaborator
National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States,

References & Publications (1)

Irwin MR, Pike JL, Cole JC, Oxman MN. Effects of a behavioral intervention, Tai Chi Chih, on varicella-zoster virus specific immunity and health functioning in older adults. Psychosom Med. 2003 Sep-Oct;65(5):824-30. — View Citation

See also
Status	Clinical Trial	Phase
Completed	`NCT00792623` - Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).	Phase 2
Enrolling by invitation	`NCT05015686` - Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old	Phase 3
Completed	`NCT00092430` - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)	Phase 3
Completed	`NCT00384397` - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers	Phase 3
Completed	`NCT00226499` - Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox	Phase 3
Completed	`NCT00402831` - ProQuad® Intramuscular vs Subcutaneous	Phase 3
Not yet recruiting	`NCT06068608` - A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy	Phase 1
Completed	`NCT00560755` - Safety Study of ProQuad® rHA in Infants (V221-037)	Phase 3
Completed	`NCT00715234` - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients	N/A
Terminated	`NCT00258726` - Immune Responses to Two Dose Varivax +/- MMR-II	Phase 1/Phase 2
Completed	`NCT03239873` - Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)	Phase 3
Completed	`NCT00751348` - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136	Phase 3
Completed	`NCT00969436` - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM	Phase 3
Completed	`NCT00566527` - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)	Phase 3
Completed	`NCT01390857` - Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)	N/A
Completed	`NCT00127010` - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Phase 3
Completed	`NCT00578175` - Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age	Phase 2
Completed	`NCT00568334` - Study of Two Formulations of GSK Biologicals' Varicella Vaccine	Phase 2
Completed	`NCT03114982` - The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age	Phase 2
Completed	`NCT00483574` - Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers	Phase 3

Tai Chi Chih and Varicella Zoster Immunity

Clinical Trial Details — Status: Completed

Administrative data

Study information